The Biggest HIV Stories to Follow in 2025
Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund, explains the biggest HIV issues anticipated this year.
Aside from the pending FDA approval of injectable lenacapavir as a form of pre-exposure prophylaxis, Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund says to expect HIV program defunding under the Trump Administration as well as updates to the Braidwood v. Becerra case, a lawsuit threatening PrEP-specific coverage requirements under the Affordable Care Act.
“The big agencies that set that help set, guide and put forward policies and furtherance of HIV prevention and HIV care, like the FDA, like the CDC, their funding is likely going to be cut,” Abrigo said in an interview with Managed Healthcare Executive.
FDA Accepts NDA for Gilead's New HIV Prevention Shot
February 18th 2025Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving this drug a priority review and expects to make a decision by June 19, 2025, according to a release.
Read More
HIV + Hepatitis Institute Welcomes RFK, Talks Importance of Ending the HIV Epidemic
February 13th 2025The group released a statement today expressing that they are eager to work with Robert F. Kennedy Jr. to eradicate HIV when steps into his role as the Secretary of Health and Human Services.
Read More
